Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Summit Therapeutics presents updated Ivonescimab data from phase II studies at ESMO 2024 annual meeting: Miami Wednesday, September 18, 2024, 15:00 Hrs [IST] Summit Therapeutics I ...

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease ...

Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentationUTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024(Nasdaq: MRUS) (Merus, the Company, we, or our), a clin ...

Continue Reading Kience booth at the ESMO 2024 Congress with the poster of the results presented. The test is claimed to be ...

in patients with advanced solid tumors as a poster presentation (Presentation Number: 1010P) at the ESMO Congress 2024. The data has also been published online as an abstract New technologies, some ...

I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly ...

Nicolas Girard, MD, head of the Curie-Montsouris Thorax Institute, discusses patient-reported outcomes (PROs) from the phase 2 LUMINOSITY trial of telisotuzumab vedotin (Teliso-V) in non–small cell ...

HADDONFIELD, NJ, USA I 16, 2024 I Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on ...